Latest Akero Therapeutics News & Updates

See the latest news and media coverage for Akero. We track all announcements, press releases, and industry mentions in real time, all in one place.

Akero Therapeutics (Akero)

Clinical-stage biotechnology company developing metabolic disease therapies

akerotx.com

Headquarters: South San Francisco, United States
Founded year: 2017
Company type: Public company
Number of employees: 50–75
Industry: Pharmaceuticals

Last updated October 28

Latest news about Akero Therapeutics (Akero)

In short: Akero was acquired by Novo Nordisk in a deal worth up to $5.2 billion

Company announcements

December 22, 2025 Akero

Akero Therapeutics reflects on 2025 achievements

They showed cirrhosis reversal in Phase 2b trial, completed Phase 3 enrollment, and finalized Novo Nordisk acquisition. They anticipate 2026 progress.

December 9, 2025 Akero

Akero Therapeutics completes acquisition by Novo Nordisk

This milestone advances efruxifermin for MASH treatment, complementing Novo Nordisk's metabolic disease portfolio.

November 7, 2025 Akero

Akero Therapeutics shares new efruxifermin data at AASLD

They present posters and oral sessions on antifibrotic activity from SYMMETRY and HARMONY trials.

October 9, 2025 Akero

Akero Announces Acquisition By Novo Nordisk For Up To $5.2 Billion

Novo Nordisk will pay $54 per share plus contingent value rights for efruxifermin approval by June 2031 in this all-cash transaction.

Media coverage

October 28 Idéal Investisseur

Novo Nordisk puts $5.2 billion into Akero Therapeutics to strengthen its position in liver metabolic diseases

The Danish giant Novo Nordisk announced on October 9, 2025 the acquisition of Akero Therapeutics for an amount that could reach $5.2 billion. This operation...

April 21 MSN

Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion

Under the terms of the deal, Novo Nordisk will initially pay $54 a share in cash, or $4.7 billion, upon closing. Akero shareholders will also...

April 8 Pharmaceutical Executive

Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics | PharmExec

Novo Nordisk acquires Akero Therapeutics to enhance its portfolio with efruxifermin, a promising treatment for metabolic dysfunction-associated steatohepatitis.

March 19 Kavout

What Drove Avoro Capital Advisors' Strategic Exit from Akero Therapeutics

Avoro Capital Advisors sold its entire stake in Akero Therapeutics for $187.81 million. This strategic exit followed Novo Nordisk's $5.2 billion acquisition of Akero. The...

Never miss news about Akero

Track Akero and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Akero competitors & trending companies

Browse news for competitors to Akero and other trending companies.